CLINICAL TRIALS PROFILE FOR JNJ-70033093

Clinical Trials for JNJ-70033093

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03891524 ↗	A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery	Completed	Bristol-Myers Squibb	Phase 2	The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment or objectively confirmed symptomatic], nonfatal pulmonary embolism [PE], or any death) during the treatment period.
NCT03891524 ↗	A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery	Completed	Janssen Research & Development, LLC	Phase 2	The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment or objectively confirmed symptomatic], nonfatal pulmonary embolism [PE], or any death) during the treatment period.
NCT04206488 ↗	A Study of JNJ-70033093 and Digoxin in Healthy Participants	Recruiting	Bristol-Myers Squibb	Phase 1	The purpose of this study is to evaluate the potential pharmacokinetic (PK) interaction between JNJ-70033093 and digoxin in healthy participants after single dose administration and at steady state.
NCT04206488 ↗	A Study of JNJ-70033093 and Digoxin in Healthy Participants	Recruiting	Janssen Research & Development, LLC	Phase 1	The purpose of this study is to evaluate the potential pharmacokinetic (PK) interaction between JNJ-70033093 and digoxin in healthy participants after single dose administration and at steady state.
NCT04223349 ↗	A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants	Completed	Janssen Research & Development, LLC	Phase 1	The purpose of this study is to characterize the pharmacokinetic (PK) of multiple twice-daily doses of JNJ-70033093 in healthy participants and to assess the effects of dosing time and food on the PK of single-dose of JNJ-70033093 in healthy participants.
NCT04388501 ↗	A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants	Recruiting	Janssen Pharmaceutica N.V., Belgium	Phase 1	The purpose of this study is to evaluate the potential pharmacokinetics (PK) interaction between milvexian and atorvastatin (and its metabolites) in healthy participants at steady state.

Clinical Trial Conditions for JNJ-70033093

Condition Name

Condition Name
Intervention	Trials
Healthy	7
Ischemic Stroke; Ischemic Attack, Transient	1
Acute Coronary Syndrome	1
Arthroplasty, Replacement, Knee	1

Condition MeSH

Condition MeSH
Intervention	Trials
Ischemic Attack, Transient	1
Ischemia	1
Cerebral Infarction	1
Syndrome	1

Clinical Trial Locations for JNJ-70033093

Trials by Country

Trials by Country
Location	Trials
United States	67
Canada	10
Belgium	7
Greece	3
United Kingdom	3

Trials by US State

Trials by US State
Location	Trials
Texas	3
Florida	3
Colorado	3
California	3
Arizona	3

Clinical Trial Progress for JNJ-70033093

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	1
Phase 1	9

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	5
Completed	3
Not yet recruiting	3

Clinical Trial Sponsors for JNJ-70033093

Sponsor Name

Sponsor Name
Sponsor	Trials
Janssen Research & Development, LLC	9
Bristol-Myers Squibb	4
Janssen Pharmaceutica N.V., Belgium	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	15
Other	2